Several markers including predictive biomarkers such as PD-L1 expression by tumor cells [16, 39], tumor mutation burden [40] and DNA mismatch-repair deficiency [41] have thus been proposed to expand enrollment of patient populations that are responsive to immunotherapy. This evidence concerns the gene CD274 and neoplasm.